Overview

Central Pain Study for ABX-1431

Status:
Completed
Trial end date:
2018-07-24
Target enrollment:
Participant gender:
Summary
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy. During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Abide Therapeutics